Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41375-024-02512-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting Remission in Schizophrenia Using Machine Learning-Assessing the Impact of Sample Size and Predictor Overinclusion.
Acta Psychiatr Scand
September 2025
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Introduction: Machine learning studies sometimes include a high number of predictors relative to the number of training cases. This increases the risk of overfitting and poor generalizability. A recent study hypothesized that between-trial heterogeneity precluded generalizable outcome prediction in schizophrenia from being achieved.
View Article and Find Full Text PDFEffects of concomitant methotrexate and predictors of remission in Janus kinase inhibitor therapy for rheumatoid arthritis.
Joint Bone Spine
September 2025
Department of Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Objective: To evaluate the effects of concomitant methotrexate (MTX) and predictors of remission in rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors.
Methods: This retrospective study included 681 treatment courses in 569 patients treated with JAK inhibitors. The impact of baseline variables on achieving Clinical Disease Activity Index (CDAI) remission at 24 weeks was assessed using multivariate logistic regression analysis.
Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study.
Ren Fail
December 2025
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background: Rituximab (RTX) has become the first-line therapy for idiopathic membranous nephropathy (IMN). The safety of low-dose and long-course RTX regimen in elderly patients with IMN remains unknown.
Methods: Sixty-nine IMN patients with anti-M-phospholipase A2 receptor (PLA2R) antibodies-positive were recruited for this study.
Towards causal inference-based antidepressant selection with brain and blood biomarkers.
Neuropsychopharmacology
September 2025
Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
This report sought to employ multi-modal integration of pre-treatment brain (electroencephalogram, resting-state functional magnetic resonance imaging) and blood (immune and metabolic) biomarkers to facilitate causal inference-based treatment selection by virtue of establishing predictability of remission to multi-stage antidepressant treatment. Data from two stages of pharmacotherapy in the 'Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression' (EMBARC) study from participants with both brain and blood biomarkers were included (N = 197). Participants were initially randomized to sertraline or placebo (Stage 1), and depending on clinical response at week-8, their therapy in Stage 2 was either maintained or switched (to sertraline, if a non-responder to placebo, or to bupropion, if a non-responder to sertraline).
View Article and Find Full Text PDFDescriptive Analysis and Factors Associated With Relapse in Dogs With Presumptive Idiopathic Immune-Mediated Polyarthritis.
J Vet Intern Med
September 2025
Ecole Nationale Veterinaire d'Alfort-CHUV-AC-IMRB, Maisons-Alfort, France.
Background: Immune-mediated polyarthritis (IMPA) is a joint disease common in dogs. Although its prognosis is generally favorable, relapses are frequent, and predictive factors for relapse remain poorly characterized.
Objectives: To evaluate the outcome of medical management of IMPA in dogs and identify predictive factors for relapse.